Search form
Search
Login
Subscribe
Home
Country Intelligence
Industry Directory
Offsets / IC
Tenders
Australia
(19/week)
Haiti
(0/week)
Guyana
(0/week)
Honduras
(0/week)
Guatemala
(0/week)
View all
(19/week)
News
United States
(559/week)
Manufacturing
(388/week)
Energy
(305/week)
Technology
(408/week)
Other Energy
(276/week)
Events
About us
Who we are
Our People
Partners
Contact us
LinkedIn
Login
Twitter
Register
Home
News
Alirocumab
Apr 26, 2019
Sanofi delivers strong Q1 2019 business EPS growth of 9.4% at CER
Mar 15, 2019
Praluent® (alirocumab) now approved in European Union to reduce the risk of cardiovascular events in patients with established cardiovascular disease
Feb 11, 2019
Sanofi and Regeneron offer Praluent® (alirocumab) at a new reduced U.S. list price
Feb 07, 2019
Sanofi delivers 2018 business EPS growth of 5.1% at CER
Feb 04, 2019
CHMP Recommends Approval of Praluent® (alirocumab) Injection to Reduce Cardiovascular Risk in People with Established Atherosclerotic Cardiovascular Disease
Jan 07, 2019
Regeneron Provides Update on Commercial and Pipeline Progress at J.P. Morgan Healthcare Conference
Jan 07, 2019
Regeneron and Sanofi Restructure Immuno-Oncology Collaboration for Discovery and Development Programs
Dec 01, 2018
Regeneron Presents Positive Data at ASH for REGN1979 CD20xCD3 Bispecific Antibody in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Nov 11, 2018
ODYSSEY OUTCOMES Investigators Highlight at AHA that Praluent® (alirocumab) Injection Was Associated with Fewer Deaths from Any Cause
Nov 06, 2018
Regeneron Reports Third Quarter 2018 Financial and Operating Results
Oct 31, 2018
Sanofi Q3 2018 Performance Confirms Return to Growth
Oct 08, 2018
Libtayo® (cemiplimab-rwlc) Data at ESMO 2018 Congress Provide New Insights in Six Tumor Types Under Investigation
Sep 13, 2018
Hyperlipidemia Drugs Market Worth $22.6 Billion by 2022 | CAGR: 2.3%: Grand View Research, Inc.
Sep 12, 2018
FDA to review supplemental Biologics License Application for Praluent® (alirocumab) Injection as potential treatment to reduce major adverse cardiovascular events
Sep 12, 2018
FDA to Review Supplemental Biologics License Application for Praluent® (alirocumab)Injection as Potential Treatment to Reduce Major Adverse Cardiovascular Events
Aug 29, 2018
Lower Cholesterol Treatment Breakthrough
Aug 16, 2018
Regeneron and Teva Announce Positive Topline Phase 3 Fasinumab Results in Patients with Chronic Pain from Osteoarthritis of the Knee or Hip
Aug 13, 2018
Regeneron Provides Regulatory Update on EYLEA® (aflibercept) Injection sBLA in Wet Age-Related Macular Degeneration
Aug 02, 2018
Regeneron Reports Second Quarter 2018 Financial and Operating Results
Jul 31, 2018
Q2 2018 Performance Positions Sanofi for New Growth Phase
‹‹
Page 2
››
Latest News
May 15, 2024
VSE Corporation Prices Public Offering of Common Stock
May 15, 2024
Mitsubishi Electric and Musashi Energy Solutions Sign Partnership and Co-Development Contract
May 15, 2024
Owens Corning and Masonite Announce Successful Results of Early Participation in and Amend the Terms of...
May 15, 2024
Poulterra Revolutionizes Poultry Industry with Launch of Innovative Manure-as-a-Service Platform
May 15, 2024
Superior Plus Reports Voting Results of Annual and Special Meeting of Shareholders
May 15, 2024
Superior Plus Declares 2024 Second Quarter Dividend
May 15, 2024
Dynexus’ Rapid EIS Shows Distinct Battery Safety Advantage
May 15, 2024
Tetra Tech Launched Its 2030 Vision at Its Inaugural Investor Day
View all News
Agenda
29
October
United Kingdom
Copthorne Tara Hotel, London, UK
International Dismounted Soldier, 29-30 October 2024, Copthorne Tara Hotel, London, UK
Navigating the Evolving Battlespace: Enhancing the Capabilities of the Dismounted Soldier The modern battlefield...
24
September
United Kingdom
Hilton London Syon Park, London, UK
Defence Transformation Conference, 24-26 September 2024, Hilton London Syon Park, London, UK
Returning for its 8th year, Defence Transformation 2024 will feature an updated format that will address all aspects of...
17
June
France
Parc des Expositions de Paris Nord Villepinte ZAC Paris Nord 2, 93420 Villepinte – France (Halls 5a – 5b – 6)
Eurosatory 2024, 17 - 21 June 2024, Parc des Expositions de Paris Nord Villepinte ZAC Paris Nord 2, 93420 Villepinte – France (Halls 5a – 5b – 6)
Eurosatory 2024 There can be no sustainable world without peace and security. Founded in 1967, the exhibition...
View All Events